Our current end point findings indicated stimulated bone formation in intact

GC-treated male rats. Sal B40 alone in intact male rats significantly increased BFR/TV, Sal B 40 in GC-treated rats significantly increased Carfilzomib|PR-171 Proteasome inhibitor BFR while Sal B80 in GC-treated rats significantly increased BFR/TV by 50% and additionally increased cancellous bone mass and trabecular thickness. Taken together, the combination of improved marrow microenvironment andSal B stimulation of bone formation rate not only prevented GC - induced osteopenia but also increased cancellous bone mass. The current study used doses of 40 and 80 mg/kg gavage in rats, which is similar to the dose used in humans. Salvianolic Acid B was approved by the for clinical use in the prevention and treatment of cardiovascular diseases. The recommended dose of Salvianolic Acid B for humans. Our study examined the drug impact on body weight, organ weight, gross necropsy and CHIR-99021|CT99021 GSK-3 inhibitor histopathology both in intact rats and glucocorticoid-treated rats. No significant adverse effects on these parameters were observed. Recently reported on the toxicity of Sal A, a derivative of Sal B, in male and female dogs after a 3-month continuous intravenous infusion at doses. No significant cumulative toxicity was observed either during or days following treatment.